First in Human Study of TORL-3-600 in Participants With Advanced Cancer
Status:
Recruiting
Trial end date:
2026-09-15
Target enrollment:
Participant gender:
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and
antitumor activity of TORL-3-600 in patients with advanced cancer